Xenon Pharmaceuticals Inc.
XENE

$3.03 B
Marketcap
$39.80
Share price
Country
$0.46
Change (1 day)
$50.99
Year High
$28.20
Year Low
Categories

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

marketcap

P/E ratio for Xenon Pharmaceuticals Inc. (XENE)

P/E ratio as of 2023: -16.89

According to Xenon Pharmaceuticals Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -16.89. At the end of 2022 the company had a P/E ratio of -19.04.

P/E ratio history for Xenon Pharmaceuticals Inc. from 2011 to 2023

PE ratio at the end of each year

Year P/E ratio
2023 -16.89
2022 -19.04
2021 -17.28
2020 -18.42
2019 -8.18
2018 -3.55
2017 -1.66
2016 -5.19
2015 -7.29
2014 4.80
2013 7.93
2012 -22.18
2011 -7.95